Introduction
============

As in many other parts of the world, cancer is the leading cause of death and is a major public health problem in Korea. According to the annual report of the Korea Central Cancer Registry, 224,177 patients were newly diagnosed with cancer in 2012, and overall incidence rates have increased by 3%-4% per year \[[@b1-crt-2015-370]\]. The number of individuals diagnosed with cancer has increased each year, due in large part to aging and particularly for some cancers (e.g., breast and colorectal cancer) because of the increasing prevalence of obesity attributed to westernized eating habits, and for some other cancers (e.g., thyroid and prostate cancer) because of the development of diagnostic tools and as a result of a medical system that encourages cancer screening \[[@b2-crt-2015-370]\].

In addition to surgery and chemotherapy, radiation therapy (RT) is one of the three primary modalities for modern cancer treatment. As the market and clinical demand for RT grow in importance, providing accurate, nationally based databases concerning the clinical status of RT has become important for understanding the status and development of cancer treatment in Korea. Official records concerning the clinical status of RT were reported from 1999 to 2006 in Korea \[[@b3-crt-2015-370]-[@b6-crt-2015-370]\]. The results were compiled from questionnaires mailed to radiation oncology facilities. A website with relevant RT statistics from the Korean Society for Radiation Oncology (KOSRO) was recently developed and is being operated as an on-line statistical program \[[@b7-crt-2015-370]\]; these developments may be helpful for taking inventory of the RT equipment and for evaluating the manpower status for radiation oncology in Korea. However, these approaches require a long period of time as well as the cooperation of all RT facilities for data collection.

In this study, we analyzed the clinical status of RT in 2009 and 2013 in Korea using open claims data from the Health Insurance Review and Assessment Service (HIRA).

Materials and Methods
=====================

The claims data from the HIRA are open access to approved researchers who submit a profile of their work and R&D plan. The claims data from the HIRA contain information on 46 million patients per year who account for 90% of the total population in Korea; the claims data include information regarding patients' diagnoses, treatment, procedures, surgical history, and prescription drugs, which provide a valuable resource for healthcare research \[[@b8-crt-2015-370]\].

The customized source population criteria for this study are shown in [Table 1](#t1-crt-2015-370){ref-type="table"}. The source population consisted of all patients who had any of the International Classification of Diseases 10 (ICD-10) cancer diagnoses (C00-C97) and at least one of the procedure codes related to receiving RT ([Table 2](#t2-crt-2015-370){ref-type="table"}) from January to December in 2009 and 2013. Patients who received two or more sessions of RT with interruption through January to December were counted as one patient. Patients with a diagnostic code concerning metastases (C77-79) were categorized as having received RT to a metastatic site. Patients with two or more diagnostic codes related to malignant neoplasms were categorized as having received RT to the metastatic site, followed by the main, secondary, and third diagnostic codes.

The site of RT category classification was based on the annual reports from the KOSRO, except for the breast and thyroid, which were classified independently rather than as part of the thoracic category.

Results
=======

The total numbers of patients who underwent RT in 2009 and 2013 were 42,483 and 56,850, respectively. The total numbers of male and female patients who received RT were 20,012 and 22,471 in 2009, 26,936 and 29,914 in 2013, respectively ([Fig. 1](#f1-crt-2015-370){ref-type="fig"}). The numbers of patient who received RT in 2009 and 2013 by cancer sites and sex are shown in [Table 3](#t3-crt-2015-370){ref-type="table"}. The five most frequent sites for patients who underwent RT in 2009 were as follows: metastatic (brain, bone, lymph node, and others), breast, gastrointestinal, thoracic, and gynecologic. However, the fifth most frequent site in 2013 was head and neck cancer instead of gynecologic cancer. The three leading sites among male patients were metastatic, gastrointestinal, and thoracic cancer, and breast, metastatic, and gynecologic cancer among women, in that order. The numbers of patients who received RT according to site and age group in 2013 are shown in [Table 4](#t4-crt-2015-370){ref-type="table"}. The most common treatment site was the central nervous system for those in their 20s or younger, while the breast was the most frequent site through the 30s to 50s, and metastasis was most common for those in their 60s or older. Similar trends were observed in 2009.

Discussion
==========

This study was conducted to analyze the clinical status of RT in 2009 and 2013 in Korea using claims data from the HIRA. Using the annual reports of KOSRO, we determined that the total number of patients who received RT increased by 33% every 4 years ([Fig. 2](#f2-crt-2015-370){ref-type="fig"}). Although the absolute number of patients who received RT has been increasing steadily, because the cancer incidence has also increased steadily over the same period \[[@b9-crt-2015-370]-[@b12-crt-2015-370]\], the percentages of cancer patients who underwent irradiation were expected to be consistently below 30% over the period from 1999 to 2013.

Breast, gastrointestinal, and genitourinary cancers have shown the steepest increase in number and proportion ([Fig. 3](#f3-crt-2015-370){ref-type="fig"}). This tendency could be explained not only by the increasing cancer incidence, but also by the increasing evidence supporting the use of RT through well-designed studies and with the advancement of RT techniques.

This approach, using claims data from the HIRA, could reduce the amount of time required to obtain data from participants from each RT facility and eliminate the possible recall bias associated with questionnaire-based studies. In addition, claims data from the HIRA can be analyzed easily by age group, as shown in [Table 4](#t4-crt-2015-370){ref-type="table"}.

However, this study had several limitations. Because the claims data from the HIRA only include the insured cases, uninsured treatments, such as intensity modulated RT, cannot be analyzed. In addition, we included patients with the 'C' code and excluded benign disease. Therefore, patients who had a 'D' diagnostic code, which is expected to be a somewhat large portion of patients with ductal carcinoma in situ of the breast treated by RT, were excluded from this analysis. As a result, the actual number of patients who received RT is expected to be more than what is reported. To the contrary, because the patients who received RT on multiple sites including primary or metastatic sites throughout the treated years could be re-counted as annual new patients, the actual total number of patients who received RT is expected to be less than what we reported. Therefore, the annual number of patients who received RT should be considered under these limitations. In addition, the 'metastasis' category, which accounts for the largest proportion of patients in this study, may reduce the number of patients who received RT to each primary cancer site. Because we cannot distinguish whether the patients actually received RT to a metastatic site or to a primary site in cases with a metastatic diagnostic code, we assumed that the patients with metastatic diagnostic codes received RT to a metastatic site. As a result, the proportions of patients who received RT to metastatic sites were high in this study. According to the RT statistics data published in KOSRO, the portion of the 'metastasis' category for all patients receiving RT was 15%-18% between 1999 and 2006 \[[@b3-crt-2015-370]-[@b6-crt-2015-370]\]; however, the proportions of the 'metastasis' category were 32% in 2009 and 27% in 2013 in the current study. This may have been an under-estimation of the number of each primary cancer site.

Conclusion
==========

In conclusion, the number of patients who received RT in Korea has shown a steady increase; however, the percentages of cancer patients who underwent irradiation were expected to still be below 30%. Although the use of claims data from the HIRA has some limitations, it provided useful cumulative clinical data supporting RT as one of the main modalities for cancer treatment in Korea.
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###### 

The customized source population

  List                          Criterion
  ----------------------------- ------------------------------------------------
  Treatment period              2009 Jan 1-2009 Dec 31, 2013 Jan 1-2013 Dec 31
  Type of healthcare facility   Tertiary, secondary
  Diagnostic code               C00-C97
  Type of insurance             Health insurance, medical aid
  Hospital region               National
  Sex                           Male, female
  Age                           All ages

###### 

Procedure codes related to radiation therapy

  Procedure code   Name of procedure codes
  ---------------- ---------------------------------------------------------
  HD051            Teletherapy-Low energy-Single port
  HD052            Teletherapy-Middle energy-Single port
  HD053            Teletherapy-High energy-Single port
  HD054            Teletherapy-Low energy-Paralleled opposed ports
  HD055            Teletherapy-Middle energy-Paralleled opposed ports
  HD056            Teletherapy-High energy-Paralleled opposed ports
  HD058            Rotational irradiation-Middle energy radiation therapy
  HD059            Rotational irradiation-High energy radiation therapy
  HD061            3-Dimensional conformal therapy
  HD080            External radioisotope therapy
  HD081-HD082      Intracavitary therapy-High dose rate
  HD083-HD084      Intracavitary therapy-Low dose rate
  HD085-HD086      Interstitial, intraluminal therapy-High dose rate
  HD088            Interstitial, intraluminal therapy-Low dose rate
  HD089            Brachytherapy
  HD091            Total body irradiation
  HD092            Total body lymph node irradiation
  HD093            Total skin electron beam therapy
  HD110            Fractionated stereotactic radiotherapy
  HD111-HD112      Body stereotactic radiosurgery-Using linear accelerator
  HD113            Cranial stereotactic radiosurgery-Gamma knife
  HD114            Cranial stereotactic radiosurgery-Cyber knife
  HD115            Cranial stereotactic radiosurgery-Linear accelerator
  HD121            Proton therapy
  HD211-HD212      Stereotactic body radiosurgery-Using cyber knife
  HZ271            Intensity modulated radiation therapy

###### 

Distribution of patients who received radiation therapy according to tumor site and sex in 2009 and 2013

  Site                         Sub-site (diagnostic code)          No. of patients in 2009   No. of patients in 2013                              
  ---------------------------- ----------------------------------- ------------------------- ------------------------- -------- -------- -------- --------
  Metastasis                   (C77-C79)                           7,435                     6,280                     13,715   8,529    6,894    15,423
  Breast                       (C50)                               11                        8,731                     8,742    17       13,480   13,497
  Gastrointestinal             Colorectum (C18-C20)                2,129                     1,109                     3,238    2,416    1,203    3,619
                               Hepatobiliary (C22-C24)             1,706                     566                       2,272    2,329    746      3,075
                               Esophagus (C15)                     737                       43                        780      992      79       1,071
                               Pancreas (C25)                      226                       147                       373      397      275      672
                               Stomach (C16)                       232                       108                       340      290      133      423
                               Anus (C21)                          49                        72                        121      62       109      171
                               Small bowel (C17)                   13                        5                         18       17       12       29
                               Other (C26)                         2                         0                         2        1        0        1
                               Subtotal                            5,094                     2,050                     7,144    6,504    2,557    9,061
  Thoracic                     Lung (C34)                          2,576                     551                       3,127    4,073    1,045    5,118
                               Thymus (C37)                        86                        70                        156      115      80       195
                               Mediastinum (C38)                   20                        4                         24       31       7        38
                               Trachea (C33)                       6                         7                         13       6        8        14
                               Other (C39)                         1                         0                         1        1        0        1
                               Subtotal                            2,689                     632                       3,321    4,226    1,140    5,366
  Head and neck                Larynx (C32)                        575                       32                        607      832      36       868
                               Oral cavity (C02-C06)               183                       89                        272      304      178      482
                               Oropharynx (C01, C09-C10)           193                       35                        228      395      66       461
                               Nasopharynx (C11)                   125                       42                        167      271      92       363
                               Salivary gland (C07-C08)            127                       77                        204      163      116      279
                               Hypopharynx (C12-C13)               181                       14                        195      248      17       265
                               Paranasal sinus (C31)               57                        27                        84       82       39       121
                               Nasal cavity (C30)                  48                        19                        67       64       34       98
                               Eye and orbit (C69)                 17                        16                        33       23       16       39
                               Lip (C00)                           8                         2                         10       5        5        10
                               Other (C14)                         4                         1                         5        15       0        15
                               Subtotal                            1,518                     354                       1,872    2,402    599      3,001
  Gynecologic                  Uterine cervix (C53)                \-                        1,942                     1,942    \-       2,095    2,095
                               Uterine corpus (C54-C55)            \-                        521                       521      \-       618      618
                               Ovary and tubes (C56)               \-                        72                        72       \-       111      111
                               Vagina and vulva (C51-C52)          \-                        87                        87       \-       84       84
                               Other (C57-C58)                     \-                        3                         3        \-       5        5
                               Subtotal                            \-                        2,625                     2,625    \-       2,913    2,913
  Genitourinary                Prostate (C61)                      847                       \-                        847      2,097    \-       2,097
                               Ureter and bladder (C66-C67)        178                       52                        230      291      69       360
                               Kidney (C64-C65)                    47                        17                        64       77       38       115
                               Penis and testis (C60, C62-C63)     34                        \-                        34       53       \-       53
                               Other (C68)                         0                         4                         4        0        7        7
                               Subtotal                            1,106                     73                        1,179    2,518    114      2,632
  Central nervous system       Brain (C70-C71)                     700                       557                       1,257    815      656      1,471
                               Spinal cord (C72)                   20                        12                        32       17       24       41
                               Other (C47)                         11                        7                         18       23       18       41
                               Subtotal                            731                       576                       1,307    855      698      1,553
  Lymphoma                     Hodgkin\'s disease (C81)            58                        23                        81       61       26       87
                               Non-Hodgkin\'s lymphoma (C82-C88)   541                       398                       939      676      542      1,218
                               Other (C96)                         2                         2                         4        9        7        16
                               Subtotal                            601                       423                       1,024    746      575      1,321
  Soft tissue                  (C46, C49)                          177                       140                       317      295      219      514
  Myeloma and plasmacytoma     (C90)                               132                       125                       257      179      163      342
  Leukemia                     (C91-C95)                           159                       115                       274      170      132      302
  Skin                         (C44)                               84                        83                        167      123      102      225
  Thyroid                      (C73)                               57                        122                       179      72       134      206
  Malignant melanoma           (C43)                               38                        34                        72       68       61       129
  Primary bone and cartilage   (C40-C41)                           69                        42                        111      59       38       97
  Endocrine                    (C74-C75)                           26                        14                        40       37       22       59
  Others                       (C45, C48, C76, C80, C97)           85                        52                        137      136      73       209
  Total                                                            20,012                    22,471                    42,483   26,936   29,914   56,850

###### 

The number of patients who received radiation therapy by site and age group in 2013

  Treatment site               Age group   Total                                       
  ---------------------------- ----------- ------- -------- -------- -------- -------- --------
  Metastasis                   150         614     2,150    4,351    4,240    3,918    15,423
  Breast                       137         1,411   4,976    4,412    1,872    689      13,497
  Gastrointestinal             15          178     880      2,605    2,753    2,630    9,061
  Respiratory                  18          60      300      989      1,774    2,225    5,366
  Head and neck                54          132     343      816      867      789      3,001
  Gynecologic                  45          257     611      911      529      560      2,913
  Genitourinary                13          20      58       289      854      1,398    2,632
  Central nervous system       227         159     285      343      300      239      1,553
  Lymphoma                     126         127     215      333      243      277      1,321
  Soft tissue                  61          53      75       99       105      125      518
  Myeloma and plasmacytoma     0           8       34       87       118      95       342
  Leukemia                     118         66      47       45       23       3        302
  Skin                         3           11      25       32       42       112      225
  Thyroid                      7           10      26       60       42       61       206
  Malignant melanoma           0           8       17       36       37       31       129
  Primary bone and cartilage   25          5       12       26       16       13       97
  Endocrine                    18          5       10       8        10       8        59
  Others                       9           6       24       51       53       62       205
  All cancer                   1,026       3,130   10,088   15,493   13,878   13,235   56,850
